Searched over 200M research papers for "lisinopril statin"
10 papers analyzed
These studies suggest that combining lisinopril with statins can effectively reduce proteinuria, improve renal function, enhance antioxidant enzyme activities, and improve endothelial functions, while also being a viable treatment option for hypertension and dyslipidemia.
20 papers analyzed
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to manage hypertension and heart failure. Statins, such as simvastatin, atorvastatin, and pravastatin, are primarily prescribed to lower cholesterol levels and reduce cardiovascular risk. Recent research has explored the combined use of these drugs to enhance therapeutic outcomes, particularly in conditions involving cardiovascular and renal complications.
Combining lisinopril with statins has shown promising results in severe nephropathy models. In a study using a rat model of passive Heymann nephritis (PHN), the combination of lisinopril and simvastatin significantly reduced proteinuria and improved renal function compared to either drug alone. This combination also limited glomerulosclerosis, tubular damage, and interstitial inflammation, suggesting a synergistic effect in protecting renal structures and function .
The combination of lisinopril and simvastatin has been observed to influence antioxidant enzyme activities in erythrocytes. Studies have shown that both treatments increase catalase activity and decrease glutathione peroxidase activity, with a significant rise in superoxide dismutase activity after prolonged treatment. These changes suggest enhanced antioxidative defense mechanisms, which may contribute to the overall cardiovascular and renal protective effects .
Additionally, the combination therapy has been found to normalize erythrocyte arginase activity and increase plasma nitric oxide metabolites, indicating improved endothelial function and reduced oxidative stress.
In patients with coronary artery disease, both lisinopril and statins have been shown to acutely improve endothelial dysfunction. This improvement is attributed to increased availability of nitric oxide, which enhances vasodilation and reduces vascular resistance. The acute effects of these drugs on vascular reactivity highlight their potential in managing acute cardiovascular events and improving long-term cardiovascular health.
In patients with Behçet's disease, a chronic inflammatory vasculitis, both atorvastatin and lisinopril significantly improved endothelial function as measured by flow-mediated dilatation. This suggests that these drugs can be beneficial in managing vascular complications associated with inflammatory conditions.
For individuals with HIV infection on antiretroviral therapy, lisinopril has shown potential anti-inflammatory benefits, reducing high-sensitivity C-reactive protein (hsCRP) and tumor necrosis factor-alpha (TNF-α) levels. However, adherence to lisinopril was a challenge, indicating the need for strategies to improve compliance in this population.
The combination of lisinopril and statins offers significant therapeutic benefits, particularly in managing severe nephropathy, improving antioxidant defenses, and enhancing endothelial function. These effects are beneficial across various conditions, including cardiovascular diseases, inflammatory vasculitis, and HIV infection. Future research should focus on optimizing adherence and exploring long-term outcomes to fully harness the potential of this combination therapy.
Most relevant research papers on this topic